S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
The gold catalyst we’ve waited for (Ad)
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
My No. 1 dividend stock for a LIFETIME of income. (Ad)
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
GameStop Shares Surge On Surprise Profit
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
The gold catalyst we’ve waited for (Ad)
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
My No. 1 dividend stock for a LIFETIME of income. (Ad)
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
GameStop Shares Surge On Surprise Profit
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
The gold catalyst we’ve waited for (Ad)
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
My No. 1 dividend stock for a LIFETIME of income. (Ad)
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
GameStop Shares Surge On Surprise Profit
S&P 500   3,936.97
DOW   32,030.11
QQQ   306.12
3 Dividend Contenders to Buy Now for Long-Term Gains Later
The gold catalyst we’ve waited for (Ad)
3 Tech Stocks Well Positioned For Growth At A Reasonable Price
These 3 Dividend Growers Yield More Than the 10-Year Note
The gold catalyst we’ve waited for (Ad)
Closing prices for crude oil, gold and other commodities
Seesaw Effect: As Banks Drop, These 3 Stocks Are Going Up
My No. 1 dividend stock for a LIFETIME of income. (Ad)
AI Is Giving 3 Marketing & Ad Firms Revenue & Earnings Boost
GameStop Shares Surge On Surprise Profit
NASDAQ:OMCL

Omnicell - OMCL Stock Forecast, Price & News

$55.77
-3.02 (-5.14%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$55.73
$58.95
50-Day Range
$51.51
$60.43
52-Week Range
$46.11
$137.86
Volume
670,277 shs
Average Volume
538,315 shs
Market Capitalization
$2.51 billion
P/E Ratio
557.70
Dividend Yield
N/A
Price Target
$71.67

Omnicell MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
28.5% Upside
$71.67 Price Target
Short Interest
Bearish
5.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Omnicell in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$756,982 Sold Last Quarter
Proj. Earnings Growth
142.31%
From $0.52 to $1.26 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

156th out of 986 stocks

Electronic Computers Industry

2nd out of 5 stocks


OMCL stock logo

About Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

Should You Hold Omnicell (OMCL)?
Could This Be The Biggest Stock Of 2023?
This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!pixel
Should You Hold Omnicell (OMCL) for the Long-Term?
Could This Be The Biggest Stock Of 2023?
This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!pixel
Omnicell: Poor Track Record, Staying On The Sidelines
These 4 Toxic Stocks May Bring Bad Luck to Your Portfolio
Omnicell (OMCL) Failed to Meet Expectations in Q3
Should You Hold Omnicell (OMCL) Stock?
Omnicell (OMCL) Stock Declined on Management Guidance
Omnicell (OMCL) Q3 Earnings Beat Estimates, Guidance Cut
See More Headlines
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Company Calendar

Last Earnings
11/02/2021
Today
3/23/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electronic computers
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:OMCL
CUSIP
68213N10
Employees
4,230
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$71.67
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+28.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$5.65 million
Pretax Margin
-0.19%

Debt

Sales & Book Value

Annual Sales
$1.30 billion
Cash Flow
$4.21 per share
Book Value
$25.52 per share

Miscellaneous

Free Float
43,746,000
Market Cap
$2.51 billion
Optionable
Optionable
Beta
0.89

Social Links


Key Executives

  • Randall A. LippsRandall A. Lipps
    Chairman, President & Chief Executive Officer
  • Peter J. KuipersPeter J. Kuipers
    Chief Financial Officer & Executive Vice President
  • Giri Chodavarapu
    Chief Information Officer
  • Virad Gupta
    Chief Technology Officer & Senior Vice President
  • Roxanne Turner
    Chief Compliance & Privacy Officer













OMCL Stock - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMCL shares.
View OMCL analyst ratings
or view top-rated stocks.

What is Omnicell's stock price forecast for 2023?

8 brokerages have issued twelve-month price objectives for Omnicell's shares. Their OMCL share price forecasts range from $54.00 to $120.00. On average, they expect the company's stock price to reach $71.67 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price.
View analysts price targets for OMCL
or view top-rated stocks among Wall Street analysts.

How have OMCL shares performed in 2023?

Omnicell's stock was trading at $50.42 at the start of the year. Since then, OMCL stock has increased by 10.6% and is now trading at $55.77.
View the best growth stocks for 2023 here
.

When is Omnicell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our OMCL earnings forecast
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) released its quarterly earnings results on Tuesday, November, 2nd. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.63 by $0.45. The business earned $296.40 million during the quarter, compared to the consensus estimate of $283.82 million. Omnicell had a trailing twelve-month return on equity of 7.11% and a net margin of 0.44%. During the same period in the previous year, the company posted $0.40 EPS.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its first quarter 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of $0.04-$0.14 for the period, compared to the consensus EPS estimate of $0.19. The company issued revenue guidance of $273.00 million-$283.00 million, compared to the consensus revenue estimate of $275.46 million.

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by many different institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (3.64%), Clearbridge Investments LLC (2.65%), Geneva Capital Management LLC (2.17%), ArrowMark Colorado Holdings LLC (1.92%), Geode Capital Management LLC (1.89%) and Dimensional Fund Advisors LP (1.71%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends
.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $55.77.

How much money does Omnicell make?

Omnicell (NASDAQ:OMCL) has a market capitalization of $2.51 billion and generates $1.30 billion in revenue each year. The company earns $5.65 million in net income (profit) each year or $0.10 on an earnings per share basis.

How many employees does Omnicell have?

The company employs 4,230 workers across the globe.

Does Omnicell have any subsidiaries?
The following companies are subsidiares of Omnicell: 340B Investment LLC, 340B Link Business, 340B Link LLC, 340B Solutions LLC, Aesynt, Ateb Inc., FDS Amplicare, FDS Amplicare Company, FDS Inc., FDS Insurance Agency Inc., Flavma Inc., InPharmics, MTS Medication Technologies Inc., MTS Medication Technologies Inc., MTS Packaging Systems Inc., MarkeTouch Media LLC, MarkeTouch Media LLC, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd, Omnicell B.V., Omnicell GmbH, Omnicell India Private Limited, Omnicell International LLC, Omnicell Limited, Omnicell Pty Ltd, Omnicell S.r.l., Omnicell SAS, ReCept Cityview LLC, ReCept F&M LLC, ReCept Group Inc., ReCept Healthcare Services L.P., ReCept Holdings Inc., ReCept LLC, ReCept One LLC, ReCept Pharmacy, ReCept Pharmacy L.P., RxInnovation Inc., and ateb Inc..
Read More
How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (650) 251-6100, via email at ir@omnicell.com, or via fax at 847-596-3402.

This page (NASDAQ:OMCL) was last updated on 3/23/2023 by MarketBeat.com Staff